Vivanco et al. [16] demonstrated that the disappointing clinical activity of first-generation EGFR inhibitors in GBM versus lung cancer might be attributed to the different conformational requirements of mutant EGFR. The gene discussed is EGFR; the disease is lung carcinoma.